B of A Securities Maintains Underperform on Harmony Biosciences Hldgs, Lowers Price Target to $28
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Jason Gerberry maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Underperform and lowers the price target from $32 to $28.
B of A Securities analyst Jason Gerberry maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Underperform and lowers the price target from $32 to $28.